2A Pharma is a privately owned Swedish/Danish biotech company. The company was founded in December 2016 and has a patented, highly novel and innovative vaccine platform based on adeno-associated virus-like particles (AAVLPs). Targeting a growing $2bn+ global market currently dominated by one player, the clinical stage lead drug candidate 2AP01 is a human papillomavirus vaccine based on AAVLPs with insertion of L2 minor HPV capsid peptides, providing protection against all tested HPV strains and formulated without adjuvants. In addition, 2A Pharma is developing a pipeline of other AAVLP based prophylactic and therapeutic vaccines in a range of therapeutic areas including cancer, allergy, viral infections, neurodegenerative, and autoimmune diseases.